implications of the fda approval of combination talazoparib & enzalutamide therapy
Published 1 year ago • 465 plays • Length 9:29Download video MP4
Download video MP3
Similar videos
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:13
late breaking - fda approves pembrolizumab for new indication of nmibc
-
20:14
nmibc post-fda approval of new drugs
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
11:48
cardiovascular implications in the treatment of prostate cancer
-
33:19
castration resistant prostate cancer - developments and challenges from 2020
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
10:07
pca commentary: sequencing bipolar androgen therapy (bat) with xtandi- an effective option
-
8:33
titan phase 3 trial with apalutamide in metastatic castration sensitive prostate cancer
-
28:45
technical and diagnostic limitations to partial prostate ablation for prostate cancer
-
3:19
fda approval of durvalumab for advanced bladder cancer
-
1:43
international prostate cancer update 2024: an invitation from the chair
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
9:40
standard treatments and global perspective 1080p
-
1:14
rationale of phase iii pcs5 trial of hypofractionated radiotherapy for prostate cancer